Download PDF
CC BY 4.0 · Rev Bras Ginecol Obstet 2022; 44(03): 231-237
DOI: 10.1055/s-0042-1742411
Original Article
Fetal Medicine

Could Aspirin Treatment Modify the Assessment of the Uterine Arteries?

O tratamento com aspirina pode modificar a avaliação das artérias uterinas?
Gabriela Marisol Vallejo 
1   Universidad El Bosque, El Bosque Research Group of Maternal Fetal, Medicine and Gynecology, Ecodiagnóstico El Bosque SAS, Los Cobos Medical Center, Bogotá, Colombia
,
Montserrat Uriel 
1   Universidad El Bosque, El Bosque Research Group of Maternal Fetal, Medicine and Gynecology, Ecodiagnóstico El Bosque SAS, Los Cobos Medical Center, Bogotá, Colombia
,
Alexandra Porras-Ramírez 
2   Research Group Community Medicine and Collective Health, El Bosque University, Los Cobos Medical Center, Bogotá, Colombia
,
Ximena Carolina Romero 
1   Universidad El Bosque, El Bosque Research Group of Maternal Fetal, Medicine and Gynecology, Ecodiagnóstico El Bosque SAS, Los Cobos Medical Center, Bogotá, Colombia
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objective To analyze whether acetylsalicylic (ASA) intake modifies the mean uterine arteries pulsatility index (UtA-PI) at the 2nd or 3rd trimester in a cohort of pregnant women with abnormal mean UtA-PI at between 11 and 14 weeks of gestation.

Methods This is a retrospective cohort study. Singleton pregnancies with abnormal mean UtA-PI at between 11 and 14 weeks of gestation were studied. The participants were divided into 3 groups: 1) If the participant did not take ASA during pregnancy; 2) If the participant took ASA before 14 weeks of gestation; and 3) If the participant took ASA after 14 weeks of gestation. The mean UtA-PI was evaluated at the 2nd and 3rd trimesters, and it was considered to improve when it decreased below the 95th percentile. The prevalence ratio (PR) and the number needed to treat (NNT) were calculated.

Results A total of 72 participants with a mean UtA-PI > 95th percentile at the 1st trimester of gestation were evaluated. Out of the 18 participants who took ASA, 8 participants started it before 14 weeks of gestation and 10 after. A total of 33.3% of these participants had improved the mean UtA-PI at the 2nd and 3rd trimesters of gestation, although it was not statistically significant (p = 0.154). The prevalence ratio was 0.95 (95% confidence interval [CI]: 0.31–1.89), but between the 1st and 2nd trimesters of gestation, the PR was 0.92 (95%CI: 0.21–0.99) and it was statistically significant.

Conclusion The present work demonstrates a modification of the mean UtA-PI in participants who took ASA compared with those who did not. It is important to check if ASA can modify the normal limits of uterine arteries because this could have an impact on surveillance.

Resumo

Objetivo Analisar se a ingestão de acetilsalicílico (ASA) modifica o índice médio de pulsatilidade das artérias uterinas (UtA-PI) no 2° ou 3° trimestre em uma coorte de gestantes com média anormal de UtA-PI entre 11 e 14 semanas.

Métodos Este é um estudo de coorte retrospectivo. Gravidezes únicas com média anormal de UtA-PI entre 11 e 14 semanas foram estudadas. As participantes foram divididas em 3 grupos: 1) Se a participante não tomou ASA durante a gravidez, 2) Se a participante tomou AAS antes das 14 semanas e 3) Se a participante tomou ASA após 14 semanas. A média do UtA-PI foi avaliada nos 2° e 3° trimestres e considerou-se que melhorava quando diminuía < 95° percentil. Foram calculados a razão de prevalência (RP) e o número necessário para tratar (NNT).

Resultados Foram avaliadas 72 participantes com média de UtA-PI > 95° percentil no 1° trimestre de gravidez. Das 18 participantes que tomaram ASA, 8 participantes começaram antes de 14 semanas e 10 depois. Um total de 33,3% desses participantes melhoraram a média de UtA-PI nos 2° e 3° trimestres, embora não tenha sido estatisticamente significante (p = 0,154). A razão de prevalência foi de 0,95 (intervalo de confiança [IC95%]: 0,31–1,89), mas entre os 1° e o 2° trimestres, a RP foi de 0,92 (IC95%: 0,21–0,99) e foi estatisticamente significativa.

Conclusão O presente trabalho demonstra uma modificação da média de UtA-PI em participantes que faziam uso de ASA em comparação com aqueles que não faziam. É importante verificar se o ASA pode modificar os limites normais das artérias uterinas porque isso pode ter um impacto na vigilância.

Keywords

aspirin - pre-eclampsia - ultrasonography - doppler - uterine artery

Palavras-chave

aspirina - pré-eclâmpsia - ultrassonografia - doppler - artéria uterina

Collaborations

All authors contributed with the project and data interpretation, the writing of the article, the critical review of the intellectual content, and with the final approval of the version to be published.




Publication History

Received: 03 March 2021

Accepted: 11 November 2021

Article published online:
09 February 2022

© 2022. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Lisonkova S, Sabr Y, Mayer C, Young C, Skoll A, Joseph KS. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol 2014; 124 (04) 771-781 DOI: 10.1097/AOG.0000000000000472.
    CrossrefPubMedGoogle Scholar
  • 2 Ahumada JS, Barrera AM, Canosa D. et al. Risk factors for preterm birth in Bogotá, D.C., Colombia. Rev Fac Med (Caracas) 2020; 68 (04) 556-563 DOI: 10.15446/revfacmed.v68n4.79702. Spanish
    CrossrefPubMedGoogle Scholar
  • 3 Uriel M, Romero XC. Reality of preeclampsia in Colombian pregnant women. J Gynecol 2016; 1 (01) 000105
    PubMedGoogle Scholar
  • 4 Romero XC, Gutiérrez AM, Rojas NA. et al. Incidence of hypertensive disorders in pregnancy and clinical-demographic characteristics in pregnant women in three institutions in Bogotá, D.C., Colombia. Investig Segur Soc Salud. 2018; 20 (02) 21-30
    CrossrefPubMedGoogle Scholar
  • 5 Guzmán-Yara YN, Parra-Amaya E, Javela-Rugeles JD. Expectant management in non-severe pre-eclampsia, obstetric and perinatal outcomes in a high complexity hospital in Neiva (Colombia). Colomb J Obstet Gynecol 2018; 69 (03) 160-168 DOI: 10.18597/rcog.3075.
    CrossrefPubMedGoogle Scholar
  • 6 Buitrago-Gutiérrez G, Castro-Sanguino A, Cifuentes-Borrero R, Ospino-Guzman MP, Arevalo-Rodriguez I, Gomez-Sánchez PI. [Clinical practice guidelines for approaching pregnancy-associated hypertensive complications]. Colomb J. Obstet Gynecol 2013; 64 (03) 289-326 Spanish
    PubMedGoogle Scholar
  • 7 Amaya-Guío J, Díaz-Cruz LA, Cardona-Ospina A, Rodríguez-Merchán DM, Osorio-Sánchez D, Barrera-Barinas A. [Clinical practice guidelines for the prevention and early detection of pregnancy disorders]. Colomb J. Obstet Gynecol 2013; 64 (03) 245-288 Spanish
    PubMedGoogle Scholar
  • 8 Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin J Am Soc Nephrol 2016; 11 (06) 1102-1113 DOI: 10.2215/CJN.12081115.
    CrossrefPubMedGoogle Scholar
  • 9 Scazzocchio E, Oros D, Diaz D, Ramirez JC, Ricart M, Meler E. et al. Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11-14 weeks: a randomized controlled study. Ultrasound Obstet Gynecol 2017; 49 (04) 435-441 DOI: 10.1002/uog.17351.
    CrossrefPubMedGoogle Scholar
  • 10 Lin S, Shimizu I, Suehara N, Nakayama M, Aono T. Uterine artery Doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstet Gynecol 1995; 85 (5 Pt 1): 760-765 DOI: 10.1016/0029-7844(95)00020-r.
    CrossrefPubMedGoogle Scholar
  • 11 Papageorghiou AT, Yu CK, Bindra R, Pandis G, Nicolaides KH. Fetal Medicine Foundation Second Trimester Screening Group. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001; 18 (05) 441-449 DOI: 10.1046/j.0960-7692.2001.00572.x.
    CrossrefPubMedGoogle Scholar
  • 12 Poon LC, Karagiannis G, Leal A, Romero XC, Nicolaides KH. Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks. Ultrasound Obstet Gynecol 2009; 34 (05) 497-502 DOI: 10.1002/uog.7439.
    CrossrefPubMedGoogle Scholar
  • 13 O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M. et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol 2017; 49 (06) 756-760 DOI: 10.1002/uog.17455.
    CrossrefPubMedGoogle Scholar
  • 14 O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC. et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol 2016; 214 (01) 103.e1-103.e12 DOI: 10.1016/j.ajog.2015.08.034.
    CrossrefPubMedGoogle Scholar
  • 15 Rolnik DL, Wright D, Poon LCY, Syngelaki A, O'Gorman N, de Paco Matallana C. et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol 2017; 50 (04) 492-495 DOI: 10.1002/uog.18816.
    CrossrefPubMedGoogle Scholar
  • 16 Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation. Am J Obstet Gynecol 2016; 215 (01) 87.e1-87.e17 DOI: 10.1016/j.ajog.2016.02.016.
    CrossrefPubMedGoogle Scholar
  • 17 Sharma N, Srinivasan S, Srinivasan KJ, Nadhamuni K. Role of aspirin in high pulsatility index of uterine artery: a consort study. J Obstet Gynaecol India 2018; 68 (05) 382-388 DOI: 10.1007/s13224-017-1058-4.
    CrossrefPubMedGoogle Scholar
  • 18 Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369 (9575): 1791-1798 DOI: 10.1016/S0140-6736(07)60712-0.
    CrossrefPubMedGoogle Scholar
  • 19 Rolnik DL, Wright D, Poon LC. O'Gorman, Syngelaki, de Paco Matallana, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377 (07) 613-622 DOI: 10.1056/NEJMoa1704559.
    CrossrefPubMedGoogle Scholar
  • 20 Tonni G, Araujo Júnior E, Bonasoni MP. Physiopathology. In: Nardozza L, Araujo Júnior E, Rizzo G, Deter R. editors. Fetal growth restriction: current evidence and clinical practice. Cham: Springer; 2019: 41-64
    CrossrefGoogle Scholar
  • 21 Bujold E, Morency AM, Roberge S, Lacasse Y, Forest JC, Giguère Y. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can 2009; 31 (09) 818-826 DOI: 10.1016/S1701-2163(16)34300-6.
    CrossrefPubMedGoogle Scholar
  • 22 Bhide A, Acharya G, Bilardo CM, Brezinka C, Cafici D, Hernandez-Andrade E. et al. ISUOG practice guidelines: use of Doppler ultrasonography in obstetrics. Ultrasound Obstet Gynecol 2013; 41 (02) 233-239 DOI: 10.1002/uog.12371.
    CrossrefPubMedGoogle Scholar
  • 23 Sotiriadis A, Hernandez-Andrade E, da Silva Costa F, Ghi T, Glanc P, Khalil A. et al; ISUOG CSC Pre-eclampsia Task Force. ISUOG Practice Guidelines: role of ultrasound in screening for and follow-up of pre-eclampsia. Ultrasound Obstet Gynecol 2019; 53 (01) 7-22 DOI: 10.1002/uog.20105.
    CrossrefPubMedGoogle Scholar
  • 24 Plasencia W, Maiz N, Poon L, Yu C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2008; 32 (02) 138-146 DOI: 10.1002/uog.5402.
    CrossrefPubMedGoogle Scholar
  • 25 Martin AM, Bindra R, Curcio P, Cicero S, Nicolaides KH. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation. Ultrasound Obstet Gynecol 2001; 18 (06) 583-586 DOI: 10.1046/j.0960-7692.2001.00594.x.
    CrossrefPubMedGoogle Scholar
  • 26 Gómez O, Figueras F, Fernández S, Bennasar M, Martínez JM, Puerto B. et al. Reference ranges for uterine artery mean pulsatility index at 11-41 weeks of gestation. Ultrasound Obstet Gynecol 2008; 32 (02) 128-132 DOI: 10.1002/uog.5315.
    CrossrefPubMedGoogle Scholar
  • 27 Coutinho LM, Scazufca M, Menezes PR. Methods for estimating prevalence ratios in cross-sectional studies. Rev Saude Publica 2008; 42 (06) 992-998 DOI: 10.1590/S0034-89102008000600003.
    CrossrefPubMedGoogle Scholar
  • 28 Deddens JA, Petersen MR. Approaches for estimating prevalence ratios. Occup Environ Med 2008; 65 (07) 481-, 501–506 DOI: 10.1136/oem.2007.034777.
    CrossrefPubMedGoogle Scholar
  • 29 Schiaffino A, Rodríguez M, Pasarín MI, Regidor E, Borrell C, Fernández E. [Odds ratio or prevalence ratio? Their use in cross-sectional studies]. Gac Sanit 2003; 17 (01) 70-74 DOI: 10.1016/s0213-9111(03)71694-x.
    CrossrefPubMedGoogle Scholar
  • 30 Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done?. Occup Environ Med 1998; 55 (04) 272-277 DOI: 10.1136/oem.55.4.272.
    CrossrefPubMedGoogle Scholar
  • 31 World Medical Association. WMA Declaration of Helsinki: ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, Jun 1964 [Internet]. 2018 [cited 2020 Dec 15]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
    PubMedGoogle Scholar
  • 32 Ministerio de Salud. Resolución No. 8430, de 4 de octubre de 1993 [Internet]. Por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. 1993 [cited 2020 Dec 15]. Available from: https://www.urosario.edu.co/Escuela-Medicina/Investigacion/Documentos-de-interes/Files/resolucion_008430_1993.pdf
    PubMedGoogle Scholar
  • 33 Haapsamo M, Martikainen H, Räsänen J. Low-dose aspirin reduces uteroplacental vascular impedance in early and mid gestation in IVF and ICSI patients: a randomized, placebo-controlled double-blind study. Ultrasound Obstet Gynecol 2008; 32 (05) 687-693 DOI: 10.1002/uog.6215.
    CrossrefPubMedGoogle Scholar